Galderma Sees Aesthetics Portfolio Boost from Rising Use of GLP-1 Medications
The increasing use of GLP-1 medications, such as Ozempic and Wegovy, is driving demand for Galderma's aesthetics treatments like fillers to address 'Ozempic face.' CEO Flemming Ørnskov noted that about 10% of U.S. adults are now using these drugs, contributing to a significant growth opportunity in the company’s portfolio.
Topics: aesthetics portfolio growth GLP-1 drugs weight loss treatments